Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/102247
Title: Obtusilactone B from Machilus Thunbergii targets barrier-to-autointegration factor to treat cancer
Authors: Kim, Wanil
Lyu, Ha-Na
Kwon, Hyun-Sook
Kim, Ye Seul
Lee, Kyung-Ha
Kim, Do-Yeon
Chakraborty, Goutam
Choi, Kwan Yong
Yoon, Ho Sup
Kim, Kyong-Tai
Keywords: Biological Sciences
Issue Date: 2013
Source: Kim, W., Lyu, H.-N., Kwon, H.-S., Kim, Y. S., Lee, K.-H., Kim, D.-Y., et al. (2013). Obtusilactone B from Machilus Thunbergii Targets Barrier-to-Autointegration Factor to Treat Cancer. Molecular Pharmacology, 83(2), 367-376.
Series/Report no.: Molecular pharmacology
Abstract: Targeting specific molecules is a promising cancer treatment because certain types of cancer cells are dependent on specific oncogenes. This strategy led to the development of therapeutics that use monoclonal antibodies or small-molecule inhibitors. However, the continued development of novel molecular targeting inhibitors is required to target the various oncogenes associated with the diverse types and stages of cancer. Obtusilactone B is a butanolide derivative purified from Machilus thunbergii. In this study, we show that obtusilactone B functions as a small-molecule inhibitor that causes abnormal nuclear envelope dynamics and inhibits growth by suppressing vaccinia-related kinase 1 (VRK1)–mediated phosphorylation of barrier-to-autointegration factor (BAF). BAF is important in maintaining lamin integrity, which is closely associated with diseases that include cancer. Specific binding of obtusilactone B to BAF suppressed VRK1-mediated BAF phosphorylation and the subsequent dissociation of the nuclear envelope from DNA that allows cells to progress through the cell cycle. Obtusilactone B potently induced tumor cell death in vitro, indicating that specific targeting of BAF to block cell cycle progression can be an effective anticancer strategy. Our results demonstrate that targeting a major constituent of the nuclear envelope may be a novel and promising alternative approach to cancer treatment.
URI: https://hdl.handle.net/10356/102247
http://hdl.handle.net/10220/19055
ISSN: 1521-0111
DOI: 10.1124/mol.112.082578
Schools: School of Biological Sciences 
Rights: © 2013 The American Society for Pharmacology and Experimental Therapeutics.
Fulltext Permission: none
Fulltext Availability: No Fulltext
Appears in Collections:SBS Journal Articles

SCOPUSTM   
Citations 20

23
Updated on Mar 6, 2024

Web of ScienceTM
Citations 20

21
Updated on Oct 28, 2023

Page view(s) 10

790
Updated on Mar 18, 2024

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.